EUCTR2011-000285-35-DK进行中（未招募）不适用
An international, multi-centre, randomised, stratified, double-blinded,placebo-controlled, 4-parallel group trial investigating the efficacy and safetyof three different dose levels of CRD007 administered twice daily for 1 yearto subjects with AAA (The AORTA trial). - CRD007 for the treatment of AAA
Cardoz AB0 个研究点目标入组 300 人开始时间: 2011年4月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Infrarenal abdominal aortic aneurysm with a maximum diameter between =39 mm and
- •2. Age =50 years
- •3. Following receipt of verbal and written information about the trial, the subject has
- •provided signed informed consent before any trial related activity is carried out
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 270
排除标准
- •1. Previous infra-renal aortic surgery
- •2. Planned major surgery
- •3. Known aortic dissection
- •4. Known diabetes
- •5. Treatment with systemic corticosteroids or any other systemic immunomodulatory therapy
- •6. Known or suspected inherited connective tissue disorders (i.e. Marfan or Vascular Ehlers
- •Danlos syndrome)
- •7. Calculated CLCR < 30 ml/min5
- •8. Known significant liver disease (e.g. acute clinical hepatitis, chronic active hepatitis or
- •ALT >3 x the ULN6)
- •9. Known HIV infection at the time of screening
- •10. Serious concomitant illness associated with a life expectancy less than 2 years
- •11. Active severe infection, any other concurrent disease or medical conditions that are
- •deemed to interfere with the conduct of the trial as judged by the investigator
- •12. Clinically significant cardiac disease including unstable angina, acute myocardial
- •infarction within six months from screening and congestive heart failure (NYHA III-IV
- •according to the New York Heart Association (NYHA) functional classification system)
- •13. Significant concurrent, uncontrolled medical condition including, but not limited to, renal,
- •hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or
- •psychiatric disease evaluated by the investigator to interfere with effect of the trial drug
- •14. Subjects known or suspected of not being able to comply with this trial protocol (e.g. due
- •to alcoholism, drug dependency or psychological disorder)
- •15. Receipt of prior experimental agents within 30 days prior to screening
- •16. Current participation in any other interventional clinical trial
- •17. Subjects with known uncontrolled allergic conditions or allergy/hypersensitivity to any
- •component of the trial drug or placebo excipients
研究者
相似试验
进行中（未招募）
不适用
An international multi-centre one-year trial of effects and side-effects of CRD007 tablets for treatment of aneurysm (dilation) of the aorta (the largest artery in the body) in the abdominal cavity.Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through theabdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA isgenerally asymptomatic and the greatest concern is the risk of rupture, which causes severepain, massive internal hemorrhage, and, without prompt treatment, death.MedDRA version: 13.1Level: LLTClassification code 10000054Term: Abdominal aortic aneurysmSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-000285-35-GBCardoz AB300
进行中（未招募）
不适用
An international multi-centre one-year trial of effects and side-effects of CRD007 tablets for treatment of aneurysm (dilation) of the aorta (the largest artery in the body) in the abdominal cavity.Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through theabdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA isgenerally asymptomatic and the greatest concern is the risk of rupture, which causes severepain, massive internal hemorrhage, and, without prompt treatment, death.MedDRA version: 14.1Level: LLTClassification code 10000054Term: Abdominal aortic aneurysmSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-000285-35-SECardoz AB300
已完成
不适用
An international, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, 52-week gastrointestinal clinical safety study to demonstrate that COX189 (400 mg od) reduces the risk to develop complicated ulcers as compared to NSAlDs (naproxen 500 mg bid and ibuprofen 800 mg tid), in rheumatoid arthritis and osteoarthritis patients-M069-M139M069M139PER-028-01OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
1 期
Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.Peripheral artery diseaseMedDRA version: 18.0 Level: LLT Classification code 10053375 Term: Peripheral revascularization System Organ Class: 100000004865EUCTR2014-005569-58-FRBayer HealthCare AG6,500
进行中（未招募）
不适用
An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEAEUCTR2006-001786-42-GRsanofi-Aventis recherche & developpement3,200